PCI Biotech Holding ASA

As of June 30, 2023, PCI Biotech Holding ASA has 37.33M shares outstanding.

These figures are as of June 30, 2023.

As of June 30, 2023, PCI Biotech Holding ASA maintains a current ratio of 9.69, meaning it holds 9.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.22, indicating moderate leverage, while an interest coverage ratio of 45.43 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2023, PCI Biotech Holding ASA posted a negative return on equity (ROE) of -8.63, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -39.94, reflecting losses generated across the asset base.

These figures cover the twelve months ended June 30, 2023. Free cash flow yield is negative at -38.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.63, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PCI Biotech Holding ASA shareholders.

PCI Biotech Holding ASA's most recent stock split took place on September 17, 2018 with a 1000:1077 split ratio.

As of June 30, 2023, PCI Biotech Holding ASA has an Altman Z-Score of 7.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.